25 May 2013
Keywords: Vifor Pharma, Galencia, PA21, Feseniusm Ph III, Regulatory filings
Article | 09 July 2012
The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia in patients with chronic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2012
10 July 2012
24 May 2013
© 2013 thepharmaletter.com